# Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Canonical URL: https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results
Ticker: PRAX
Company: Praxis Precision Medicines
Source: Praxis Precision Medicines
Published: 2026-02-19 12:30 EST
Original Source URL: https://investors.praxismedicines.com
## Summary

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the  U.S. Food and Drug Administration (FDA) Pre-launch activities for ulixacaltamide and relutrigine are

## Article Body
Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the  U.S. Food and Drug Administration (FDA) Pre-launch activities for ulixacaltamide and relutrigine are
## Recent Company News
- 2026-06-01 20:15 EST — [Praxis Precision Medicines Provides Vormatrigine Program Update](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-provides-vormatrigine-program-update) — Source: Praxis Precision Medicines
- 2026-05-07 12:00 EST — [Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-first-quarter-2026-financial-results) — Source: Praxis Precision Medicines
- 2026-05-05 20:01 EST — [Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Praxis Precision Medicines
- 2026-05-04 20:01 EST — [Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026-and-participate-in-upcoming-investor-conference) — Source: Praxis Precision Medicines
- 2026-04-14 11:30 EST — [Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-announces-fda-acceptance-of-new-drug-application-for-ulixacaltamide-hcl-in-patients-with-essential-tremor) — Source: Praxis Precision Medicines
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)